LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

DexCom Inc

Geschlossen

BrancheGesundheitswesen

85.47 -0.21

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

84.68

Max

85.96

Schlüsselkennzahlen

By Trading Economics

Einkommen

-46M

105M

Verkäufe

-78M

1B

KGV

Branchendurchschnitt

63.947

56.602

EPS

0.32

Gewinnspanne

10.174

Angestellte

10,200

EBITDA

-109M

134M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+15.48% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

24. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.2B

33B

Vorheriger Eröffnungskurs

85.68

Vorheriger Schlusskurs

85.47

Nachrichtenstimmung

By Acuity

50%

50%

371 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

DexCom Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Okt. 2024, 09:10 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

26. Juli 2024, 20:16 UTC

Ergebnisse

These Stocks Moved the Most Today: DexCom, 3M, Nvidia, Bristol Myers, Coursera, Biogen, Charter, Deckers, and More -- Barrons.com

26. Juli 2024, 09:13 UTC

Top News
Heiße Aktien

Stocks to Watch: DexCom, Coinbase, 3M, Hermès -- WSJ

26. Juli 2024, 08:56 UTC

Top News

These Stocks Are Moving the Most Today: DexCom, Deckers, Coursera, Ford, Alphabet, Bristol Myers, 3M, and More -- Barrons.com

27. Juni 2024, 16:01 UTC

Ergebnisse

ResMed Stock Is Down Because of GLP-1 Concerns. It Shouldn't Be. -- Barrons.com

Peer-Vergleich

Kursveränderung

DexCom Inc Prognose

Kursziel

By TipRanks

15.48% Vorteil

12-Monats-Prognose

Durchschnitt 98.93 USD  15.48%

Hoch 109 USD

Tief 85 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für DexCom Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

17 ratings

16

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

71.66 / N/AUnterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

371 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.